| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
40,782 |
30,322 |
$614K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,531 |
11,844 |
$153K |
| 62323 |
|
2,196 |
1,301 |
$84K |
| 64635 |
|
1,277 |
675 |
$62K |
| 64493 |
|
2,117 |
1,013 |
$60K |
| 64636 |
|
1,687 |
673 |
$47K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
11,884 |
7,500 |
$35K |
| 96130 |
|
4,585 |
3,444 |
$34K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
8,361 |
4,850 |
$30K |
| J3300 |
Injection, triamcinolone acetonide, preservative free, 1 mg |
3,920 |
1,130 |
$28K |
| 99152 |
|
3,585 |
1,676 |
$24K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
608 |
484 |
$23K |
| 64494 |
|
2,112 |
1,010 |
$19K |
| 64495 |
|
1,857 |
884 |
$15K |
| 20611 |
|
1,007 |
486 |
$12K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
514 |
392 |
$11K |
| 96138 |
|
4,981 |
3,745 |
$10K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
3,526 |
1,935 |
$9K |
| 27096 |
|
182 |
104 |
$9K |
| 20610 |
|
427 |
226 |
$6K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
2,730 |
1,589 |
$6K |
| 77002 |
|
430 |
230 |
$5K |
| 99153 |
Mod sedat endo service >5yrs |
2,727 |
1,158 |
$4K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
479 |
328 |
$4K |
| 99406 |
|
1,572 |
1,154 |
$3K |
| 80305 |
|
1,450 |
1,077 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
464 |
286 |
$3K |
| J3490 |
Unclassified drugs |
701 |
314 |
$974.53 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
102 |
76 |
$710.83 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
3,227 |
1,441 |
$667.61 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
252 |
180 |
$607.78 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
90 |
71 |
$338.70 |
| 76942 |
|
27 |
12 |
$303.68 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
90 |
65 |
$176.62 |
| 99156 |
|
34 |
17 |
$109.40 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
483 |
227 |
$87.70 |
| 99157 |
|
34 |
17 |
$83.00 |
| 64490 |
|
25 |
13 |
$63.17 |
| 64491 |
|
25 |
13 |
$31.36 |
| G9717 |
Documentation stating the patient has had a diagnosis of bipolar disorder |
2,299 |
1,766 |
$16.67 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
61 |
42 |
$3.83 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
18,332 |
14,459 |
$0.23 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
12,796 |
10,052 |
$0.06 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
7,772 |
6,190 |
$0.04 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
9,131 |
7,215 |
$0.04 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
1,375 |
1,157 |
$0.02 |
| G8482 |
Influenza immunization administered or previously received |
740 |
624 |
$0.01 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
796 |
672 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
3,142 |
2,540 |
$0.00 |
| 1101F |
|
1,017 |
816 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
3,865 |
3,077 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
1,132 |
923 |
$0.00 |
| G9908 |
Patient identified as tobacco user did not receive tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
435 |
356 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
392 |
331 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
2,643 |
2,073 |
$0.00 |
| 1036F |
|
1,915 |
1,511 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
1,177 |
978 |
$0.00 |
| J1094 |
Injection, dexamethasone acetate, 1 mg |
134 |
116 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
40 |
35 |
$0.00 |
| 1111F |
|
99 |
74 |
$0.00 |
| 1123F |
|
42 |
39 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
8,145 |
6,503 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
2,128 |
1,663 |
$0.00 |
| 3288F |
|
939 |
718 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
731 |
572 |
$0.00 |
| G8511 |
Screening for depression documented as positive, follow-up plan not documented, reason not given |
33 |
32 |
$0.00 |
| 4004F |
|
522 |
436 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
636 |
533 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
875 |
705 |
$0.00 |
| 1124F |
|
249 |
205 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
158 |
132 |
$0.00 |
| 4040F |
|
300 |
259 |
$0.00 |
| G9500 |
Radiation exposure indices documented in final report for procedure using fluoroscopy |
192 |
125 |
$0.00 |
| G8785 |
Blood pressure reading not documented, reason not given |
46 |
36 |
$0.00 |